Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, & Xuejun Chen. (2024). Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study. Wiley.
Chicago Style (17th ed.) CitationJia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, and Xuejun Chen. Evaluation of the Cardiac Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B‐cell Malignancies: Results from the CITADEL‐101 Study. Wiley, 2024.
MLA (9th ed.) CitationJia Li, et al. Evaluation of the Cardiac Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B‐cell Malignancies: Results from the CITADEL‐101 Study. Wiley, 2024.
Warning: These citations may not always be 100% accurate.